The company's product candidates include omacetaxine mepesuccinate, currently in Phase 2/3 clinical trials for chronic myelogenous leukemia, acute myelogenous leukemia, and myelodysplastic syndrome. They are also developing Quinamed, in Phase 2 clinical trials for hormone refractory prostate cancer. Founded in 1958 and headquartered in Geelong, Australia, ChemGenex Pharmaceuticals operates in both Australia and the United States.